TrialNature communications2026

Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial.

David Hsiehchen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.